A Safety and Efficacy Trial of Stannsoporfin in Neonates With Hyperbilirubinemia
A Safety and Efficacy Trial of Stannsoporfin in Neonates With Hyperbilirubinemia
It is a normal process in the human body for red blood cells to die, which makes bilirubin.

 Bilirubin is cleared away through the liver.

 Some babies are born with livers that don't work well enough yet, or their red blood cells
 are dying too fast, so the baby looks yellow (jaundice).

 This means there is too much bilirubin in the body. It can be dangerous if a baby's bilirubin
 gets too high.

 Phototherapy is what they call the lights they shine on newborn babies to help the liver get
 rid of bilirubin.

 This study tests an experimental drug to see if it can reduce how much bilirubin is being
 made in the first place.
The purpose of this study is to determine if an experimental drug, stannsoporfin, is safe and
 effective in the treatment of hyperbilirubinemia in hemolyzing neonates.
Inclusion Criteria:

 Babies may only participate if they meet all the following criteria:

 -  Is a term or late preterm baby

 -  Is at risk for protocol-defined hemolytic disease

 -  Weighs at least 2500 g (5.5 lbs)

 -  Has total serum bilirubin (TSB) a specified amount lower than the phototherapy
 threshold for the age

 -  Has parents/guardians who are willing to follow light precautions and sign informed
 consent

 Exclusion Criteria:

 The following criteria will make a baby not eligible to participate:

 -  Needs medications that may prolong the QT interval

 -  Has family history or risk factors for Long QT Syndrome, Sudden Infant Death Syndrome,
 or Porphyrias

 -  Has an Apgar score of 6 or below at age 5 minutes

 -  Has abnormalities or infections (in mother or child) that per protocol or in the
 opinion of the investigator may compromise the safety and well-being of the baby or
 analysis of study results